This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aardal, S., Helle, K. B., Elsayed, S., Reed, R. K., and Serck-Hanssen, G.,, 1993, Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J. Neuroendocrinol. 5: 405–412.
Blaschko, H., Comline, R.S., Schneider, F.H., Silver, M., and Smith, A.D., 1967, Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature (London) 215: 58–59.
Fasciotto, B.H., Trauss, C.A., Greeley, G.H., and Cohn, D.V., 1993, Parastatin (porcine chromogranin A347-41 9), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology 133: 461–466.
Fischer-Colbrie, R., Laslop, A., and Kirchmair, R., 1995, Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog. Neurobiol. 46: 49–10.
Fishbein, V.A., Coy, D.H., Hocart, S.J., Jiang, N.Y., Mrozinski, J.E., Jr., Mantey, S.A., and Jensen, R.T. 1994, A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists. Peptides 15: 95–100.
Huttner, W.B., Gerdes, H.H., and Rosa, P., 1991, The granin (chromogranin/secretogranin) family. Trends Biochem. Sci. 16: 21–30.
Livett, B.G., and Marley, P.D., 1993, Noncholinergic control of adrenal catecholamine secretion. J. Anat. 183: 277–289.
Mahata, M., Mahata, S.K., Parmer, R.J., and O’Connor, D.T., 1996, Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion. Hypertension 28: 414–420.
Mahata, S.K., Mahata, M., Parmer, R.J., and O’Connor, D.T., 1999, Desensitization of catecholamine release: The novel catecholamine release/inhibitory peptide catestatin (chromogranin A344–364) acts a! the receptor to prevent nicotinic cholinergic tolerance. J. Biol. Chem. 274: 2920–2928.
Mahata, S.K., Mahata, M., Yoo, S.H., Taupenot, L., Wu, H., Aroda, V.R., Livsey, C.V., Taulane, J.P., Goodman, M., Parmer, R.J., and O’Connor, D.T., 1998, A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis. Adv. Pharmacol. 42: 260–264.
Mahata, S.K., O’Connor, D.T., Mahata, M., Yoo, S.H., Taupenot, L., Wu, H., Gill, B.M., and Parmer, R.J., 1997, Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J. Clin. Invest. 100: 1623–1633.
Ochoa, E.L., Chattopadhyay, A., and McNamee, M.G., 1989, Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators. Cell. Mol. Neurobiol. 9: 141–178.
Robberecht, P., Gourlet, P., De Neef, P., Woussen-Colle, M.C., Vandermeers-Piret, M.C., Vandermeers, A., and Christophe, J., 1992, Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. Eur. J. Biochem. 207: 239–246.
Sanchez-Margalet, V., 1999, Modulation of insulin receptor signaling by pancreastatin in HTC hepatoma cells. Diabetologia 42: 317–325.
Simon, J.P., Bader, M.F., and Aunis, D. 1988, Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc. Natl. Acad. Sci. USA 85: 1712–1716.
Takiyyuddin, M.A., Cervenka, J.H., Hsiao, R.J., Barbosa, J.A., Parmer, R.J., and OConnor, D.T., 1990, Chromogranin A. Storage and release in hypertension. Hypertension 15: 237–246.
Tatemoto, K., Efendic, S., Mutt, V., Makk, G., Feistner, G.J., and Barchas, J.D., 1986, Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature (London) 324: 476–478.
Tsigelny, I., Mahata, S.K., Taupenot, L., Preece, N.E., Mahata, M., Khan, I., Parmer, R.J., and OConnor, D.T., 1998, Mechanism of action of chromogranin A on catecholamine release: molecular modeline of the catestatin region reveals a β-strand/loop/β-strand structure secured by hydrophobic interactions and predictive of activity. Regul. Peptides 77: 43–53.
Winkler, H., and Fischer-Colbrie, R., 1992, The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49: 497–528.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Mahata, S.K., Mahata, M., Livsey Taylor, C.V., Taupenot, L., Parmer, R.J., O’Connor, D.T. (2002). The Novel Catecholamine Release-Inhibitory Peptide Catestatin (Chromogranin A344–364). In: Helle, K.B., Aunis, D. (eds) Chromogranins. Advances in Experimental Medicine and Biology, vol 482. Springer, Boston, MA. https://doi.org/10.1007/0-306-46837-9_21
Download citation
DOI: https://doi.org/10.1007/0-306-46837-9_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46446-1
Online ISBN: 978-0-306-46837-7
eBook Packages: Springer Book Archive